Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00496327 | Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056) | PHASE3 | COMPLETED | 100 | — | — | Jun 22, 2005 | Oct 6, 2005 | Jan 18, 2019 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Open label |
| Name | Type | Description |
|---|---|---|
| Varicella Virus Vaccine Live (Oka-Merck) | BIOLOGICAL | VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose. |
Inclusion Criteria: * Healthy Children, Between 12 Months And 12 Years Of Age * Parent Or Legal Guardian Should Be Willing And Able To Sign The Informed Consent Form Prior To Entry Into The Study Exclusion Criteria: * Any Immune Impairment Or Deficiency, Neoplastic Disease, Or Depressed Immunity,...